|
|
|
|
|
by DanBC
3374 days ago
|
|
There are only about 20 - 30 "new molecular entities" approved each year. These are the ones that need most focus. How could that information be delivered to doctors without unduly influencing them or overwhelming them with junk info? |
|
The only thing I can think is to make it mandatory continued education. But even that is iffy. Part of the problem is that there's just not that much additional data on new drugs. By definition the FDA thinks the drug is safe (relatively) and effective so what's the education going to look like and who's going to put it together?